DNTH

Dianthus Therapeutics Inc

Add to Watchlist

Advanced Chart

18.760

-0.39(-2.037%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

20.570

Open

19.000

VWAP

18.91

Vol

307.02K

Mkt Cap

603.85M

Low

18.120

Amount

5.81M

EV/EBITDA(TTM)

Total Shares

29.35M

358.47M

EV/OCF(TTM)

P/S(TTM)

139.33

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

801.89K

-39.48%

900.78K

-58.53%

864.67K

-53.59%

Estimates Revision

The market is revising Upward the revenue expectations for Dianthus Therapeutics, Inc. (DNTH) for FY2025, with the revenue forecasts being adjusted by 7.2% over the past three months. During the same period, the stock price has changed by -4.24%.

Revenue Estimates for FY2025

Revise Upward

+7.2%

In Past 3 Month

Stock Price

Go Down

-4.24%

In Past 3 Month

7 Analyst Rating

152.67% Upside

Wall Street analysts forecast DNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNTH is 47.40 USD with a low forecast of 40.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

152.67% Upside

Current: 18.760

Low

40.00

Averages

47.40

High

52.00

152.67% Upside

Current: 18.760

Low

40.00

Averages

47.40

High

52.00

Guggenheim

Buy

upgrade

$84 -> $92

2025-07-28

Reason

Guggenheim

Price Target

$84 -> $92

2025-07-28

upgrade

Buy

Reason

Guggenheim raised the firm's price target on Dianthus to $92 from $84 and keeps a Buy rating on the shares. Ahead of the Phase 2 MaGic trial readout of claseprubart in gMG expected in September, the firm believes investors will benchmark claseprubart's efficacy responses to Zilbrysq Phase 2 results. The firm, which assigns 70% odds for the program to advance to Phase 3, sees greater than 100% upside potential in its "optimal scenario" and about 50% downside in case of outright failure, the analyst tells investors.

William Blair

NULL

Outperform

initiated

$47.57

2025-07-02

Reason

William Blair

Price Target

$47.57

2025-07-02

initiated

NULL

Outperform

Reason

William Blair initiated coverage of Dianthus with an Outperform rating. Dianthus is a clinical-stage biotech company developing DNTH103 for autoimmune neuromuscular indications, notes the analyst, who sees fair value of $47.57 per share.

Baird

Outperform

NULL

downgrade

$58 -> $50

2025-05-13

Reason

Baird

Price Target

$58 -> $50

2025-05-13

downgrade

Outperform

NULL

Reason

Baird lowered the firm's price target on Dianthus to $50 from $58 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where the company updated it product pipeline.

Wedbush

Laura Chico

Buy

Reiterates

$36

2025-03-12

Reason

Wedbush

Laura Chico

Price Target

$36

2025-03-12

Reiterates

Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$40

2025-03-12

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$40

2025-03-12

Reiterates

Strong Buy

Reason

Guggenheim

Yatin Suneja

Strong Buy

Reiterates

$84

2025-03-12

Reason

Guggenheim

Yatin Suneja

Price Target

$84

2025-03-12

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Dianthus Therapeutics Inc (DNTH.O) is -5.48, compared to its 5-year average forward P/E of -7.42. For a more detailed relative valuation and DCF analysis to assess Dianthus Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.42

Current PE

-5.48

Overvalued PE

-4.70

Undervalued PE

-10.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

261.97

Current PS

211.54

Overvalued PS

415.23

Undervalued PS

108.70